Cargando…

Impact of the 2014 American Academy of Pediatrics Policy on RSV Hospitalization in Preterm Infants in the United States

Despite being a leading cause of hospitalization due to lower respiratory tract infections, the treatment of respiratory syncytial virus (RSV) infection is primarily supportive. Palivizumab is the only licensed immunoprophylaxis (IP) available for preventing severe RSV infection in high-risk populat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goldstein, Mitchell, Fergie, Jaime, Krilov, Leonard R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017053/ https://www.ncbi.nlm.nih.gov/pubmed/33656649 http://dx.doi.org/10.1007/s40121-020-00388-1

Ejemplares similares

Severity and Cost of RSV Hospitalization Among US Preterm Infants Following the 2014 American Academy of Pediatrics Policy Change
por: Krilov, Leonard R., et al.
Publicado: (2021)

The 2014–2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States
por: Kong, Amanda M., et al.
Publicado: (2018)

Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017
por: Fergie, Jaime, et al.
Publicado: (2020)

740. Impact of the 2014 American Academy of Pediatrics Guidance on Respiratory Syncytial Virus Hospitalization Rates for Preterm Infants <29 Weeks Gestational Age at Birth: 2012–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Unintended Consequences Following the 2014 American Academy of Pediatrics Policy Change for Palivizumab Prophylaxis among Infants Born at Less than 29 Weeks' Gestation
por: Goldstein, Mitchell, et al.
Publicado: (2021)

Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

743. Severity and Costs of Respiratory Syncytial Virus and Bronchiolitis Hospitalization in Commercially Insured Preterm and Term Infants Before and After the 2014 American Academy of Pediatrics Guidance Change on Immunoprophylaxis
por: Krilov, Leonard R, et al.
Publicado: (2018)

Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics
por: Krilov, Leonard R., et al.
Publicado: (2020)

Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data
por: Kong, Amanda M., et al.
Publicado: (2021)

735. Severity and Healthcare Costs of Respiratory Syncytial Virus Hospitalizations in US Preterm Infants Born at 29–34 Weeks Gestation: 2014–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Modeling the Potential Impact of the 2014 American Academy of Pediatrics Respiratory Syncytial Virus Prophylaxis Guidance on Preterm Infant RSV Outcomes
por: McLaurin, Kimmie K., et al.
Publicado: (2015)

National Bronchiolitis Hospitalization Rates Among Preterm and Full Term Infants: 2010–2015
por: Krilov, Leonard R, et al.
Publicado: (2017)

2638. Respiratory Syncitial Virus Hospitalizations (RSVH) and All-Cause Bronchiolitis Hospitalizations (BH) Among 29–34 Weeks Gestational Age (wGA) Preterm Infants Before and After the 2014 American Academy of Pediatrics (AAP) Immunoprophylaxis Policy Change Using the Children’s Hospital Association’s Pediatric Health Information System (PHIS)
por: Fergie, Jaime, et al.
Publicado: (2019)

1520. Respiratory Syncytial Virus Hospitalizations (RSVH) and All-Cause Bronchiolitis Hospitalizations (BH) Among Children Aged ≤ 24 Months at the Start of RSV Season With Bronchopulmonary Dysplasia/Chronic Lung Disease of Prematurity (BPD/CLDP) Before and After the 2014 American Academy of Pediatrics (AAP) Policy
por: Fergie, Jaime, et al.
Publicado: (2020)

1513. Medically Attended Respiratory Syncytial Virus Hospitalizations (RSVH) and All-Cause Bronchiolitis Hospitalizations (BH) Among Children Aged ≤ 24 Months at RSV Season Start With Higher-Risk Congenital Heart Disease (CHD) Before and After the 2014 American Academy of Pediatrics (AAP) Policy
por: Fergie, Jaime, et al.
Publicado: (2020)

Respiratory Syncytial Virus (RSV) Update
por: Krilov, Leonard R., et al.
Publicado: (2022)

American Academy of Pediatrics 2014 Bronchiolitis Guidelines: Bonfire of the Evidence
por: Walsh, Paul, et al.
Publicado: (2015)

Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016–2017 epidemic season: a systematic review of seven Italian reports
por: Cutrera, Renato, et al.
Publicado: (2019)

RSV Disease: Current Management and the Future of Treatment and Prevention
por: Krilov, Leonard R., et al.
Publicado: (2021)

Factors associated with nonadherence to the American Academy of Pediatrics 2014 bronchiolitis guidelines: A retrospective study
por: Pittet, Laure F., et al.
Publicado: (2023)

RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020
por: Packnett, Elizabeth R., et al.
Publicado: (2022)

Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS)
por: Fergie, Jaime, et al.
Publicado: (2020)

Does RSV prophylaxis prevents future recurrent wheeze in preterm infants?
por: Ignacio, Lena, et al.
Publicado: (2013)

Risk Factors for RSV Hospitalization in Healthy Preterm Infants: A Meta-analysis
por: Abeysinghe, Shaun, et al.
Publicado: (2017)

901. MEDI8897 Prevents Serious RSV Disease in Healthy Preterm Infants
por: Pamela Griffin, Mary, et al.
Publicado: (2019)

2353. Respiratory Syncytial Virus (RSV) in Preterm Infants: Epidemiology, Clinical Pattern, and Risk Factors in a Pediatric Hospital in Argentina
por: Gentile, Angela, et al.
Publicado: (2018)

Obesity-Related Hypertension in Pediatrics, the Impact of American Academy of Pediatrics Guidelines
por: Rutigliano, Irene, et al.
Publicado: (2021)

Compliance of Parenting Magazines Advertisements with American Academy of Pediatrics Recommendations
por: Pitt, Michael B., et al.
Publicado: (2016)

The policy statement of the American academy of pediatrics – children as hematopoietic stem cell donors – a proposal of modifications for application in the UK
por: Chan, Tak Kwong, et al.
Publicado: (2013)

American Academy of Medicine
por: Dunglison, Richard J.
Publicado: (1883)

The American Academy of Medicine
Publicado: (1894)

The American Academy of Medicine
Publicado: (1878)

The American Academy of Medicine
Publicado: (1885)

The American Academy of Medicine
Publicado: (1885)

The American Academy of Medicine
Publicado: (1886)

American Academy of Medicine
Publicado: (1888)

746. Characteristics of Respiratory Syncytial Virus (RSV) Infection Among Hospitalized Adults, United States, 2014–2017
por: Kim, Lindsay, et al.
Publicado: (2018)

Efforts by the National Academy for State Health Policy
por: Fox-Grage, Wendy
Publicado: (2021)

1633. Willingness to receive maternal RSV vaccine and infant monoclonal RSV antibody
por: Gidengil, Courtney, et al.
Publicado: (2023)

1526. The economic impact of respiratory syncytial virus (RSV) in infants in the United States: systematic literature review
por: Bowser, Diana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t2s8lv6m6pjec4nu2bevj48qpa